NinaMED develops the NiNA System®, a drug-free, noninvasive, at-home therapy for overactive bladder that targets the saphenous nerve via a centralised mechanism. The company holds an exclusive license from EBT Medical, Inc. to commercialise the device. NinaMED plans to use the US$13.75M raised in its recent financing to accelerate development of the NiNA System and to support the path to an Investigational Device Exemption (IDE) application. It also intends to use funds to build out the company’s operations in Australia. The company is privately held and based in Melbourne and recently appointed a board led by Chair Ian Meredith with Non-Executive Directors Kelly Constable and Steffen Hovard.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026